Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs InMode Ltd (INMD) Price & Performance

Charles River Laboratories Intl. IncTrade
InMode LtdTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs InMode Ltd — how do they compare? Charles River Laboratories Intl. Inc trades at $281.43 (market cap $13.46B), while InMode Ltd trades at $15.25 (market cap $872.08M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 15.4× InMode Ltd's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals.

CRLINMD
Market Cap
$13.46B$872.08M
Sector
HealthTechnology
52-Week High
$282.00$16.62
52-Week Low
$145.57$12.76
Enterprise Value
$16.30B$375.42M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.

While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.

InMode Ltd

INMD trades at $15.24, up 0.33% on the day, with a neutral technical signal and mixed earnings history including a recent Q2 2026 beat. The company maintains strong profitability with a 20.69% net income margin and attractive valuation ratios, including a P/E of 12.52. Recent news highlights include Q2 2026 results consistent with the prior year and an unsolicited acquisition proposal from Steel Partners at $16.75 per share.

The stock presents a value opportunity given its low valuation multiples and high margins, but faces near-term uncertainty from shareholder activism, a securities fraud investigation, and potential acquisition volatility. Analyst sentiment is divided between Buy and Hold ratings, reflecting the balance between fundamental strength and corporate governance concerns.

Returns comparison

Trailing returns across standard periods

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About InMode Ltd

InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.

Read more on INMD